Switch to:
Also traded in: Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 4.47
REGN's Cash to Debt is ranked lower than
69% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. REGN: 4.47 )
Ranked among companies with meaningful Cash to Debt only.
REGN' s Cash to Debt Range Over the Past 10 Years
Min: 0.58  Med: 1.94 Max: No Debt
Current: 4.47
Equity to Asset 0.65
REGN's Equity to Asset is ranked lower than
54% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. REGN: 0.65 )
Ranked among companies with meaningful Equity to Asset only.
REGN' s Equity to Asset Range Over the Past 10 Years
Min: 0.18  Med: 0.54 Max: 0.93
Current: 0.65
0.18
0.93
Interest Coverage 87.91
REGN's Interest Coverage is ranked lower than
80% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. REGN: 87.91 )
Ranked among companies with meaningful Interest Coverage only.
REGN' s Interest Coverage Range Over the Past 10 Years
Min: 10.1  Med: 13.35 Max: 22.43
Current: 87.91
10.1
22.43
F-Score: 7
Z-Score: 14.31
M-Score: -2.12
WACC vs ROIC
15.17%
24.87%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 30.51
REGN's Operating margin (%) is ranked higher than
92% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. REGN: 30.51 )
Ranked among companies with meaningful Operating margin (%) only.
REGN' s Operating margin (%) Range Over the Past 10 Years
Min: -169.68  Med: -20.39 Max: 187.97
Current: 30.51
-169.68
187.97
Net-margin (%) 15.50
REGN's Net-margin (%) is ranked higher than
84% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. REGN: 15.50 )
Ranked among companies with meaningful Net-margin (%) only.
REGN' s Net-margin (%) Range Over the Past 10 Years
Min: -161.3  Med: -27.97 Max: 54.43
Current: 15.5
-161.3
54.43
ROE (%) 20.12
REGN's ROE (%) is ranked higher than
89% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. REGN: 20.12 )
Ranked among companies with meaningful ROE (%) only.
REGN' s ROE (%) Range Over the Past 10 Years
Min: -64.37  Med: -20.28 Max: 86.68
Current: 20.12
-64.37
86.68
ROA (%) 13.60
REGN's ROA (%) is ranked higher than
90% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. REGN: 13.60 )
Ranked among companies with meaningful ROA (%) only.
REGN' s ROA (%) Range Over the Past 10 Years
Min: -21.29  Med: -10.47 Max: 44.08
Current: 13.6
-21.29
44.08
ROC (Joel Greenblatt) (%) 57.18
REGN's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. REGN: 57.18 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
REGN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -191.59  Med: -33.04 Max: 168.03
Current: 57.18
-191.59
168.03
Revenue Growth (3Y)(%) 71.60
REGN's Revenue Growth (3Y)(%) is ranked higher than
95% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. REGN: 71.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
REGN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -25.3  Med: 27.55 Max: 81.3
Current: 71.6
-25.3
81.3
» REGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

REGN Guru Trades in Q1 2015

Jim Simons 167,488 sh (New)
Pioneer Investments 482 sh (New)
Ken Fisher 534 sh (+1.91%)
Frank Sands 5,010,161 sh (+0.48%)
Ron Baron 7,490 sh (unchged)
Mario Gabelli 2,190 sh (unchged)
Vanguard Health Care Fund 2,921,000 sh (unchged)
Ray Dalio Sold Out
» More
Q2 2015

REGN Guru Trades in Q2 2015

Paul Tudor Jones 400 sh (New)
Kyle Bass 2,506 sh (New)
Ray Dalio 800 sh (New)
Ken Fisher 565 sh (+5.81%)
Pioneer Investments Sold Out
Jim Simons Sold Out
Ron Baron 7,479 sh (-0.15%)
Mario Gabelli 2,145 sh (-2.05%)
Vanguard Health Care Fund 2,764,540 sh (-5.36%)
Frank Sands 4,218,968 sh (-15.79%)
» More
Q3 2015

REGN Guru Trades in Q3 2015

Paul Tudor Jones 1,090 sh (+172.50%)
Ray Dalio 1,800 sh (+125.00%)
Mario Gabelli 2,145 sh (unchged)
Kyle Bass Sold Out
Ron Baron 7,463 sh (-0.21%)
Frank Sands 4,138,184 sh (-1.91%)
Ken Fisher 504 sh (-10.80%)
Vanguard Health Care Fund 2,447,894 sh (-11.45%)
» More
Q4 2015

REGN Guru Trades in Q4 2015

Jim Simons 107,262 sh (New)
Pioneer Investments 391 sh (New)
Ken Fisher 615 sh (+22.02%)
Ray Dalio Sold Out
Vanguard Health Care Fund 2,280,494 sh (-6.84%)
Mario Gabelli 1,378 sh (-35.76%)
» More
» Details

Insider Trades

Latest Guru Trades with REGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 72.70
REGN's P/E(ttm) is ranked lower than
80% of the 365 Companies
in the Global Biotechnology industry.

( Industry Median: 28.70 vs. REGN: 72.70 )
Ranked among companies with meaningful P/E(ttm) only.
REGN' s P/E(ttm) Range Over the Past 10 Years
Min: 22.84  Med: 85.74 Max: 164.71
Current: 72.7
22.84
164.71
Forward P/E 19.27
REGN's Forward P/E is ranked lower than
57% of the 343 Companies
in the Global Biotechnology industry.

( Industry Median: 16.58 vs. REGN: 19.27 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 72.90
REGN's PE(NRI) is ranked lower than
75% of the 259 Companies
in the Global Biotechnology industry.

( Industry Median: 31.00 vs. REGN: 72.90 )
Ranked among companies with meaningful PE(NRI) only.
REGN' s PE(NRI) Range Over the Past 10 Years
Min: 23.85  Med: 84.37 Max: 165.77
Current: 72.9
23.85
165.77
P/B 10.46
REGN's P/B is ranked lower than
99.99% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 2.56 vs. REGN: 10.46 )
Ranked among companies with meaningful P/B only.
REGN' s P/B Range Over the Past 10 Years
Min: 1.43  Med: 8.70 Max: 26.42
Current: 10.46
1.43
26.42
P/S 11.08
REGN's P/S is ranked lower than
57% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 8.95 vs. REGN: 11.08 )
Ranked among companies with meaningful P/S only.
REGN' s P/S Range Over the Past 10 Years
Min: 2.06  Med: 12.82 Max: 27.7
Current: 11.08
2.06
27.7
PFCF 68.77
REGN's PFCF is ranked lower than
78% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 28.77 vs. REGN: 68.77 )
Ranked among companies with meaningful PFCF only.
REGN' s PFCF Range Over the Past 10 Years
Min: 9.29  Med: 114.06 Max: 3748
Current: 68.77
9.29
3748
POCF 34.26
REGN's POCF is ranked lower than
64% of the 380 Companies
in the Global Biotechnology industry.

( Industry Median: 27.35 vs. REGN: 34.26 )
Ranked among companies with meaningful POCF only.
REGN' s POCF Range Over the Past 10 Years
Min: 7.52  Med: 53.57 Max: 314.37
Current: 34.26
7.52
314.37
EV-to-EBIT 30.94
REGN's EV-to-EBIT is ranked lower than
67% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 19.35 vs. REGN: 30.94 )
Ranked among companies with meaningful EV-to-EBIT only.
REGN' s EV-to-EBIT Range Over the Past 10 Years
Min: -108.7  Med: -6.40 Max: 1948.4
Current: 30.94
-108.7
1948.4
EV-to-EBITDA 29.35
REGN's EV-to-EBITDA is ranked lower than
73% of the 457 Companies
in the Global Biotechnology industry.

( Industry Median: 16.36 vs. REGN: 29.35 )
Ranked among companies with meaningful EV-to-EBITDA only.
REGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -141.9  Med: -7.80 Max: 387.3
Current: 29.35
-141.9
387.3
Shiller P/E 486.97
REGN's Shiller P/E is ranked lower than
94% of the 65 Companies
in the Global Biotechnology industry.

( Industry Median: 52.59 vs. REGN: 486.97 )
Ranked among companies with meaningful Shiller P/E only.
REGN' s Shiller P/E Range Over the Past 10 Years
Min: 489.65  Med: 1778.11 Max: 35046
Current: 486.97
489.65
35046
Current Ratio 3.64
REGN's Current Ratio is ranked lower than
56% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. REGN: 3.64 )
Ranked among companies with meaningful Current Ratio only.
REGN' s Current Ratio Range Over the Past 10 Years
Min: 2.55  Med: 6.90 Max: 20.69
Current: 3.64
2.55
20.69
Quick Ratio 3.38
REGN's Quick Ratio is ranked lower than
55% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. REGN: 3.38 )
Ranked among companies with meaningful Quick Ratio only.
REGN' s Quick Ratio Range Over the Past 10 Years
Min: 2.55  Med: 6.73 Max: 20.5
Current: 3.38
2.55
20.5
Days Inventory 160.47
REGN's Days Inventory is ranked lower than
67% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. REGN: 160.47 )
Ranked among companies with meaningful Days Inventory only.
REGN' s Days Inventory Range Over the Past 10 Years
Min: 65.06  Med: 117.12 Max: 780.78
Current: 160.47
65.06
780.78
Days Sales Outstanding 102.51
REGN's Days Sales Outstanding is ranked lower than
89% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. REGN: 102.51 )
Ranked among companies with meaningful Days Sales Outstanding only.
REGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 23.13  Med: 64.12 Max: 201.38
Current: 102.51
23.13
201.38
Days Payable 99.37
REGN's Days Payable is ranked higher than
76% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. REGN: 99.37 )
Ranked among companies with meaningful Days Payable only.
REGN' s Days Payable Range Over the Past 10 Years
Min: 145.52  Med: 569.61 Max: 2718.58
Current: 99.37
145.52
2718.58

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 48.38
REGN's Price/Net Current Asset Value is ranked lower than
94% of the 849 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. REGN: 48.38 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
REGN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.34  Med: 9.59 Max: 157.38
Current: 48.38
3.34
157.38
Price/Tangible Book 10.46
REGN's Price/Tangible Book is ranked lower than
82% of the 1004 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. REGN: 10.46 )
Ranked among companies with meaningful Price/Tangible Book only.
REGN' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.54  Med: 4.94 Max: 22
Current: 10.46
1.54
22
Price/Projected FCF 8.35
REGN's Price/Projected FCF is ranked lower than
80% of the 246 Companies
in the Global Biotechnology industry.

( Industry Median: 3.24 vs. REGN: 8.35 )
Ranked among companies with meaningful Price/Projected FCF only.
REGN' s Price/Projected FCF Range Over the Past 10 Years
Min: 10.57  Med: 18.35 Max: 240.67
Current: 8.35
10.57
240.67
Price/Median PS Value 0.87
REGN's Price/Median PS Value is ranked higher than
56% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 0.87 vs. REGN: 0.87 )
Ranked among companies with meaningful Price/Median PS Value only.
REGN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.17  Med: 0.99 Max: 4.15
Current: 0.87
0.17
4.15
Price/Graham Number 6.13
REGN's Price/Graham Number is ranked lower than
84% of the 407 Companies
in the Global Biotechnology industry.

( Industry Median: 2.23 vs. REGN: 6.13 )
Ranked among companies with meaningful Price/Graham Number only.
REGN' s Price/Graham Number Range Over the Past 10 Years
Min: 1.39  Med: 6.66 Max: 10.08
Current: 6.13
1.39
10.08
Earnings Yield (Greenblatt) (%) 3.20
REGN's Earnings Yield (Greenblatt) (%) is ranked higher than
80% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. REGN: 3.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
REGN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 2.20 Max: 24.9
Current: 3.2
0.1
24.9

More Statistics

Revenue(Mil) $3731
EPS $ 5.05
Beta1.81
Short Percentage of Float4.91%
52-Week Range $350.26 - 605.93
Shares Outstanding(Mil)104.07

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 5,071 5,914 7,161
EPS($) 15.41 19.08 25.47
EPS without NRI($) 15.41 19.08 25.47

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:REGN.Mexico, REGN.Switzerland, 0R2M.UK,
Regeneron Pharmaceuticals Inc was incorporated in in the State of New York on January 1988. The Company is a biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The Company's preclinical research programs are in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. Its manufacturing facilities are located in Rensselaer, New York and consist of three buildings totaling approximately 490,000 square feet of research, manufacturing, office, and warehouse space. It currently has approximately 74,000liters of cell culture capacity at these facilities. It faces competition from pharmaceutical, biotechnology, and chemical companies. Its competitors are Genentech, Novartis, Pfizer Inc., Bayer HealthCare, Onyx Pharmaceuticals, Inc., Eli Lilly and Company, Abbott, sanofi-aventis, Merck & Co., Amgen Inc., Roche, and others. Its present and future business would be subject to regulation under the United States Atomic Energy Act, the Clean Air Act, the Clean Water Act, the Comprehensive Environmental Response, Compensation and Liability Act, the National Environmental Policy Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act, national restrictions, and other current and potential future local, state, federal, and foreign regulations.
» More Articles for REGN

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlights: Facebook, Fitbit, Regeneron Pharmaceuticals Nov 23 2015 
The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings Nov 04 2015 
Weekly CFO Sells Highlight: Acadia Healthcare, Facebook, Regeneron Pharmaceuticals Aug 24 2015 
Weekly Insider Sells Highlights: FB, AET, REGN, TYC Aug 18 2015 
Brean Capital Weighs in on Medivation Following Update on TERRAIN Study Mar 26 2015 
Can These Three BioTech Companies Make It Big? Feb 20 2015 
J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
Weekly Insider Sells Highlight: REGN, HSP, TYC, AAPL Nov 30 2014 
S&P 500 Finishes Above 2,000 Aug 27 2014 
How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 

More From Other Websites
REGENERON PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Feb 11 2016
Morgan Stanley is Wrong: This Biotech is Ready to Explode Higher Feb 11 2016
The Zacks Analyst Blog Highlights: Regeneron, Alexion, CTI BioPharma, BioCryst and Sarepta Feb 11 2016
Novartis And the Future Of Drug Pricing Feb 10 2016
Biotech Stock Roundup: Alexion, Regeneron Miss Estimates; Setback for CTI BioPharma Feb 10 2016
Regeneron Pharmaceuticals, Inc. Earnings Analysis: 2015 By the Numbers Feb 10 2016
Regeneron Q4 Earnings Miss Estimates Amid Slow Praluent Launch Feb 09 2016
[$$] Regeneron: Good Results, Great Expectations Feb 09 2016
Edited Transcript of REGN earnings conference call or presentation 9-Feb-16 1:30pm GMT Feb 09 2016
Regeneron Q4 Earnings Lag, Gives 2016 View for Eylea Sales Feb 09 2016
Regeneron sees gradual adoption of cholesterol drug Praluent Feb 09 2016
Regeneron: Get Used to Disappointment Feb 09 2016
US STOCKS-Wall St turn positive after weak start as tech rebounds Feb 09 2016
Stocks to Watch: Regeneron, Sears, Coke, XPO Feb 09 2016
Regeneron Falls on Missed Earnings Feb 09 2016
Regeneron (REGN) Misses on Q4 Earnings and Revenues Feb 09 2016
US STOCKS-Wall St set for lower open as investors seek safety Feb 09 2016
Regeneron Pharmaceuticals Inc Earnings Call scheduled for 8:30 am ET today Feb 09 2016
Regeneron Pharmaceuticals Loses 7% Following Q4 Miss Feb 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK